Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?

This publication has 19 references indexed in Scilit:

• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
  American Heart Journal, 2003
• Emerging Anticoagulant Drugs
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
• Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?
  Heart, 2003
• A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation
  New England Journal of Medicine, 2002
• A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation
  New England Journal of Medicine, 2002
• Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention
  Internal Medicine Journal, 2002
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  BMJ, 2002
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
  Pharmacogenetics, 1995
• Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project)
  BMJ, 1992